<DOC>
	<DOCNO>NCT00291876</DOCNO>
	<brief_summary>The aim study evaluate persistence hepatitis A antibodies 138 , 150 , 162 , 174,186 , 198 , 210 , 222 , 234 246 month subject receive first dose 2 dose vaccination schedule hepatitis A vaccine . This protocol post deal objective &amp; outcome measure extension phase year 11 20 . No additional subject recruit long-term follow-up .</brief_summary>
	<brief_title>Long-Term Immune Persistence GlaxoSmithKline Biologicals ' Inactivated Hepatitis A Vaccine Injected According 0 , 12-month Schedule</brief_title>
	<detailed_description>This long-term follow-up study Years 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 20 primary vaccination GSK Biologicals ' hepatitis A vaccine ( two-dose schedule ) . To evaluate long-term antibody persistence , volunteer donate blood sample Years 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 20 first vaccine dose primary vaccination course determine anti-hepatitis A ( anti-HAV ) antibody concentration . If subject become seronegative anti-HAV antibody long-term blood sampling time point ( i.e . Months 138 , 150 , 162 , 174,186 , 198 , 210 , 222 , 234 246 ) , he/ offer additional vaccine dose . A blood sample take day additional vaccination 14 day one month additional vaccination evaluate immune response follow vaccination . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 extend follow Year 20 . The study 10 phase : 100571 , 100572 , 100573 , 100574 , 100575 , 110677 , 110678 , 110679 , 110680 , 110681 .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<criteria>Subjects receive least one dose study vaccine primary study Written inform consent obtain subject blood sample visit year .</criteria>
	<gender>All</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>HAVRIXâ„¢</keyword>
	<keyword>Hepatitis A</keyword>
</DOC>